Consumer Staples Food Producers
  • Price (USD)119.85
  • Today's Change-1.60 / -1.32%
  • Shares traded27.13k
  • 1 Year change-41.75%
  • Beta1.1973
Data delayed at least 15 minutes, as of Nov 30 2022 16:39 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Medifast, Inc. sells a variety of weight loss, weight management and healthy living products all based on its own formulas under the OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home brands. The Company’s product line includes approximately 95 consumable options, including, but not limited to, bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes and soups. The Company’s nutritional products are formulated with ingredients. The processing, formulation, packaging, labeling and advertising of the Company’s products are subject to regulation by one or more federal agencies, including the Food and Drug Administration (FDA), the Federal Trade Commission (the FTC), the Consumer Product Safety Commission, the United States Department of Agriculture and the United States Environmental Protection Agency.

  • Revenue in USD (TTM)1.64bn
  • Net income in USD151.07m
  • Incorporated1989
  • Employees984.00
  • Location
    Medifast Inc11445 Cronhill DrOWINGS MILLS 21117-2270United StatesUSA
  • Phone+1 (732) 764-0619
  • Fax+1 (410) 581-8070
  • Websitehttps://medifastinc.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Hims & Hers Health Inc373.75m-83.03m1.22bn398.00--3.81--3.26-0.411-0.4111.851.541.037.22120.92939,067.80-22.82---25.76--74.62---22.22--3.79-421.020.00-------3,430.95------
Inhibrx Inc4.77m-125.50m1.26bn106.00------262.91-3.22-3.220.1226-0.89670.0325--26.3045,037.73-85.37---103.10-------2,628.87-----9.011.26---43.89---7.41------
Chinook Therapeutics Inc56.85m-117.77m1.30bn138.00--2.72--22.79-1.83-1.830.94827.440.1168--38.81411,971.00-24.19-22.27-26.02-24.07-----207.14-441.76---27.860.00--6,142.440.3698-26.11---39.87--
BridgeBio Pharma Inc88.66m-490.77m1.30bn576.00------14.68-3.35-3.350.6054-7.620.1174----153,930.60-65.73---77.58--95.11---559.83------2.99--745.14---25.36------
Keros Therapeutics Inc20.00m-81.90m1.31bn104.00--5.15--65.51-3.36-3.360.82459.240.0829--126.98333,333.30-33.95---35.61-------409.51-----43,848.000.00-------29.01------
Novavax Inc1.85bn-1.32bn1.32bn1.54k------0.7155-17.25-17.2523.84-7.210.7641--16.671,198,360.00-54.70-70.99-187.25-148.0948.93---71.59-156.111.01-60.34----141.02136.93-316.91--25.86--
Medifast Inc1.64bn151.07m1.33bn984.009.218.828.370.809613.1813.18143.0113.774.703.30--1,665,818.0043.3040.9978.9864.9172.3074.689.2210.780.5465324.700.0047.6163.2540.9359.4755.8664.0939.63
Syndax Pharmaceuticals Inc126.58m-13.95m1.34bn59.00--3.95--10.57-0.2194-0.21942.125.620.4225--49.342,145,356.00-4.65-27.65-5.07-30.65-----11.02-163.32---123.660.00005--9,109.56158.09132.34---13.15--
FibroGen Inc122.91m-361.56m1.34bn566.00--50.89--10.89-3.88-3.881.320.280.16850.53362.54217,157.30-49.77-17.36-75.76-20.8584.96---295.49-70.091.72--0.25--33.465.14-53.22--88.99--
Verve Therapeutics Inc929.00k-147.64m1.34bn113.00--2.40--1,441.62-2.90-2.900.01839.070.0017----8,221.24-27.23---28.53-------15,892.25------0.00-------163.25------
Allogene Therapeutics Inc247.00k-312.65m1.34bn356.00--1.81--5,435.61-2.20-2.200.00175.140.0003----796.77-31.79---33.54-------126,580.20------0.00-------2.71------
Rocket Pharmaceuticals Inc0.00-199.39m1.37bn151.00--3.34-----3.06-
Twist Bioscience Corp203.56m-217.86m1.39bn652.00--1.76--6.84-4.03-4.033.7714.010.24483.366.12---26.19-35.74-28.86-39.8341.3832.59-107.02-136.186.15--0.00--53.8380.02-43.24------
Rhythm Pharmaceuticals Inc16.67m-181.49m1.41bn140.00--4.97--84.84-3.59-3.590.32935.040.0447----119,035.70-48.69-41.92-52.69-45.5991.95---1,089.06-14,334.50---176.070.206------48.05---16.31--
Amphastar Pharmaceuticals Inc484.85m77.23m1.42bn1.76k19.752.8313.792.931.491.499.3210.390.70352.476.25275,327.1011.403.9613.345.0348.2540.8916.206.572.75159.720.13030.0025.1311.404,327.3744.625.13--
Data as of Nov 30 2022. Currency figures normalised to Medifast Inc's reporting currency: US Dollar USD

Institutional shareholders

52.38%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Sep 20221.74m15.82%
The Vanguard Group, Inc.as of 30 Sep 20221.55m14.07%
Renaissance Technologies LLCas of 30 Sep 2022683.81k6.21%
SSgA Funds Management, Inc.as of 30 Sep 2022376.98k3.42%
Dimensional Fund Advisors LPas of 30 Sep 2022336.17k3.05%
Rice, Hall, James & Associates LLCas of 30 Sep 2022272.87k2.48%
Principal Global Investors LLCas of 30 Sep 2022239.37k2.17%
Geode Capital Management LLCas of 30 Sep 2022217.41k1.97%
Parametric Portfolio Associates LLCas of 30 Sep 2022201.79k1.83%
Lombard Odier Asset Management (Switzerland) SAas of 30 Sep 2022150.00k1.36%
More ▼
Data from 30 Sep 2022 - 30 Sep 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.